Coding Tip: New Technology ICD-10-PCS Section “X” Drugs for FY2019
This Coding Tip was updated on 12/4/2018
RHIA, CDIP, CCS, CCS‑P, CIRCC
Executive Director Of Education
AHIMA‑Approved ICD‑10‑CM/PCS Trainer and Ambassador
Section “X” is a separate place within ICD-10-PCS for certain new technology procedures (such as new technology drugs). Section “X” does not introduce any new coding concepts or unusual guidelines for correct coding and maintains continuity with the other sections in ICD-10-PCS. The same root operation and body part values are used in section “X” as in other sections. The seventh character in section “X” is used to indicate the new technology group. This is a number or letter that changes each year that new technology codes are added. It is only used to indicate the year the code was created and all codes for that update year will have the same qualifier. The new technology drugs for FY2019 will have the qualifier/seventh character of “4” since this is the third year of ICD-10-PCS.
Section “X” codes are standalone codes. No additional codes from other sections in ICD-10-PCS are necessary for reporting as the specific procedure is described in the code title from section “X”.
New Technology section codes are easily found by looking in the ICD-10-PCS Index or the Tables. The name of the new technology device, substance or technology for a section “X” code is included as the main term. They are also listed under the main term “New Technology”.
New technology items have a new technology payment that is made in addition to the DRG payment for hospital inpatients. Missing new technology codes is a frequent error made by coders. Coders must familiarize themselves with the new technologies of each year.
There are several substance values continuing in the code table XW0 (anatomical regions, introduction) for FY2019.
- A—Bezlotoxumab Monoclonal Antibody/ZINPLAVA™ (XW033A3, XW043A3) The maximum a hospital can received for this is $1,900 as new technology payment.
- B—Cytarabine and Daunorubicin Liposome Antineoplastic/VYXEOS™ (XW033B3, XW043B3) The maximum the hospital can receive for this is $36,425 as a new technology payment.
- C—Engineered Autologous Chimeric Antigen Receptor T-Cell Immunotherapy/KTE-C19/axicabtagene ciloleucel/CAR-T therapy (XW033C3, XW043C3) The maximum payment a hospital can receive for this is $186,500 as a new technology payment
- F—Ustekinumab/STELARA™ (XW033F3, XW043F3) The maximum the hospital can receive for this is $2,400 as a new technology payment.
- 9—Defibrotide sodium/DIFETELIO® (XW03392, XW04392) The maximum the hospital can receive for this is $80,500 as a new technology payment.
There were five new substance values added to the code table XW0 (anatomical regions, introduction) for FY 2019.
- C—Axicabtagene Ciloleucel/YESCARTA™ and Tisagenlecleucel/KYMRIAH (XW033C3, XW043C3) These are two new CAR T therapies for FY2019. The maximum payment a hospital can receive for this is $186,500 as a new technology payment
- G—Plazonmicin/ZEMDRI™ (XW033G4, XZW043G4) The maximum a hospital can receive for this is $2,722.50 as a new technology payment.
- H—GIAPREZA™ (XW033H4, XW043H4) The maximum payment a hospital can receive for this is $1,500 as a new technology payment.
- D—Meropenem-vaborbactam/VABOMERE™ (XW033F3, XW043F3 – there is no unique code for VABOMERE) For FY 2019, cases “eligible for the FY 2019 new technology add-on payments will be identified by the NDC of 65293-009-01 (VABOMERE™ Meropenem-Vaborbactam Vial). Providers must code the NDC in data element LIN03 of the 837i Health Care Claim Institutional form in order to receive the new technology add-on payment for procedures involving the use of VABOMERE™” The maximum payment a hospital can receive for this is $5,544 as a new technology payment.
- 7—Andexanet alfa/AndexXa™ (XW03372, XW04372) AndexXa is a newer form of Andexanet Alfa. The maximum payment a hospital can receive for this is $14,062.50 as a new technology payment.
New Technology Drugs for 2018 – 2019
AndexXa™ (Andexanet alfa) is an antidote used to treat patients who are receiving treatment with an oral Factor Xa inhibitor who suffer a major bleeding episode and require urgent reversal of direct and indirect Factor Xa anticoagulation. Patients at high risk for thrombosis, including those who have been diagnosed with atrial fibrillation (AF) and venous thrombosis (VTE), typically receive treatment using long-term oral anticoagulation agents.
Axicabtagene Ciloleucel (YESCARTA™) and Tisagenlecleucel (KYMRIAH™). (Fights non-Hodgkin’s Lymphoma and Acute Lymphoblastic Leukemia) For these CAR T-Cell therapies. Both are given IV.
Bezlotoxumab (ZINPLAVA™) —this drug is used in patients with Clostridium difficile (C. diff) diarrhea who are already on antibiotics and have a high risk of recurrence. Up to 25% of patients with C. diff will have a recurrence of the bacteria. Use of this drug helps to reduce recurrence of the bacteria. This drug is a human monoclonal antibody targeting the C. diff toxin B and does not affect the GI microbiota like the antibacterial drugs do. This drug is administered by IV.
Cytarabine/ and Daunorubicin (VYXEOS™)—this drug is used in patients with newly diagnosed therapy related acute myeloid leukemia (t-AML) or AML. VYXEOS delivers and maintains fixed ratios of Cytarabine and Daunorubicin and provides prolonged exposure in the bone marrow. Both Cytarabine and Daunorubicin are existing chemotherapy drugs and are commonly used but VYXEOS is a specific formula of the two drugs. This is administered by IV.
Defibrotide sodium (DEFITELIO®) is treatment for patients diagnosed with hepatic veno-occlusive disease (VOD) with evidence of multiorgan dysfunction. Also known as sinusoidal obstruction syndrome. This is a life threatening complication of hematopoietic stem cell transplantation (HSCT). Treatment is 25 mg/day for 21 + days.
Engineered Autologous Chimeric Antigen Receptor T-Cell Immunotherapy/KTE-C19/axicabtagene ciloleucel/CAR-T therapy—this engineered autologous immunotherapy is used to treat patients with relapsed or refractory B-cell non-Hodgkin lymphoma who are eligible for an autologous stem cell transplant. This represents a new paradigm in antineoplastic therapy. In this, the patient’s own T-cells are harvested and engineered to target specific antigens. After this is infused back into the patient, the genetically engineered T-cells find the target cells and kill them.
GIAPREZA™ a synthetic human angiotensin II, is administered through IV infusion to raise blood pressure in adult patients who have been diagnosed with septic or other distributive shock.
Neropenem-vaborbactam (VABOMERE™) Given IV for adults with complicated UTIs and acute pyelonephritis (chills, rigors, temp higher than 38C, WBC over 10,000, etc.)
Plazonmicin (ZEMDRI™) Next generation aminoglycoside antibiotic to treat multi-drug resistant gram-negative bacteria, usually complicated UTI (cUTI) or pyelonephritis. It is given IV.
Ustekinumab (STELARA™) is an IV infusion treatment for Crohn’s disease. Only for use in patients over 18 with moderately to severely active Crohn’s disease.
AHA ICD-10-CM/PCS Coding Clinic, Fourth Quarter 2018 Page 56
The information contained in this post is valid at the time of posting. Viewers are encouraged to research subsequent official guidance in the areas associated with the topic as they can change rapidly.
This is Part 5 of a five part series on the new 2021 CPT codes. For the remaining areas we will just briefly summarize the section. Due to the intricate nature of these sections in CPT, it is recommended that the coder read the entire section notes associated with the new codes.
This is Part 4 of a five part series on the new 2021 CPT codes. In this series we will explore the CPT changes in the urinary, nervous, ocular and auditory systems. There are 2 new urinary/male reproductive system codes with no revisions or deletions; 3 new female reproductive codes with 2 deletions, 0 new with 4 deleted nervous system codes with 5 revisions; 5 new eye category III codes; and finally a 2 new auditory codes with one deletion.
This is Part 3 of a five part series on the new 2021 CPT codes. In this series we will explore the cardiovascular system CPT changes. There are 5 new cardiovascular CPT codes added with 0 deletions and 4 revisions.
This is Part 2 of a five part series on the new 2021 CPT codes. In this series we will explore the CPT changes for FY2021 and include some examples to help the coder understand the new codes. There are 0 new musculoskeletal CPT codes added with 0 deletions and 2 major revisions along with an extensive update to arthroscopic loose body removal requirements. For the respiratory system, there were 2 new codes, one code deletion and no revisions.
This is Part 1 of a five part series on the new 2021 CPT codes. In this series we will explore the CPT changes for FY2021 and include examples to help the coder understand the new codes. For 2021 in general, there were 199 new CPT codes added, 54 deleted and 69 revised.
In January, new CPT codes were released. There were 248 new CPT codes added, 71 deleted and 75 revised. Most of the surgery section changes were in the musculoskeletal and cardiovascular subsections. These included procedures such as skin grafting, breast biopsies, deep drug delivery systems, tricuspid valve repairs, aortic grafts and repair of iliac artery.
We have seen many updates and changes to COVID-19 (SARS-CoV-2) since the pandemic started. On January 1, 2021 we will see even more changes as outlined in this post. Also the CMS MS-DRG grouper will be updated to version 38.1 to accommodate the changes.
In the previous three parts of this four-part series, we discussed the new ICD-10-CM diagnosis code changes, ICD-10-PCS procedure code changes and FY2021 IPPS changes. In this last Part 4 of the series, we will review the NTAP procedure codes and reimbursement add-on payments for FY2021.
In the previous two parts of this four part series, we discussed the new ICD-10-CM diagnosis code changes and ICD-10-PC procedure code changes. In this session we will review the major IPPS changes for FY2021.
This is Part 2 of a 4 part series on the FY2021 ICD-10 Code and IPPS changes. In this part, the ICD-10-PCS procedure codes are presented. For FY2021 ICD-10-PCS there are 78,115 total codes (FY2020 total was 77,571); 556 new codes (734 new last year in FY2020)…
This is Part 1 of a 4 part series on the FY2021 changes to ICD-10 and the IPPS. In this part, we discuss some of the new ICD-10-CM diagnosis changes. Here is the breakdown: 72,616 total ICD-10-CM codes for FY2021; 490 new codes (2020 had 273 new codes); 58 deleted codes (2020 had 21 deleted codes); 47 revised codes (2020 had 30 revised codes)
Acute pulmonary edema is the rapid accumulation of fluid within the tissue and space around the air sacs of the lung (lung interstitium). When this fluid collects in the air sacs in the lungs it is difficult to breathe. Acute pulmonary edema occurs suddenly and is life threatening.
“Client S” is a small, not-for-profit, 40 bed micro-hospital in the Southeast. HIA performed a 65-record review this year for Client S and found an opportunity with 15 of them. 9 had an increased reimbursement with a total of $43,228 found.
The coma scale codes (R40.2-) can be used in conjunction with traumatic brain injury codes, acute cerebrovascular disease or sequelae of cerebrovascular disease codes. These codes are primarily for use by trauma registries, but they may be used in any setting where this information is collected. The coma scale may also be used to assess the status of the central nervous system for other non-trauma conditions, such as monitoring patients in the intensive care unit regardless of medical condition.
In the past, there had been an Excludes1 note at I46.- Cardiac arrest that excluded R57.0, Cardiac shock. HIA had also received a letter from AHA on a case in the past that had stated that only I46.- Cardiac arrest would be coded if both were documented. In addition, the Third Quarter Coding Clinic page 26 had a similar case that asked if both could be coded, and AHA had instructed that only I46.9, cardiac arrest, cause unspecified would be coded if both were documented and that the CDC would be looking at possible revision to the Excludes1 note.
A higher CMI corresponds to increased consumption of resources and increased cost of patient care, resulting in increased reimbursement to the facility from government and private payers, like CMS. We know that documentation directly impacts coding.
Lately we have seen several cases where the endarterectomy was assigned along with the coronary artery bypass (CABG) procedure when being performed on the same vessel to facilitate the CABG. A coronary artery endarterectomy is not always performed during a CABG procedure, so when it is performed it becomes confusing as to whether to code it separately or not.
Assign code Z20.828, “Contact with and (suspected) exposure to other viral communicable diseases” for all patients who are tested for COVID-19 and the results are negative, regardless of symptoms, no symptoms, exposure or not as we are in a pandemic.
The Centers for Medicare & Medicaid Services (CMS) announced new procedure codes for treatments of COVID-19 – effective as of August 1, 2020. Among the new codes are Section X New Technology codes for the introduction or infusion of therapeutics including Remdesivir, Sarilumab, Tocilizumab, transfusion of convalescent plasma, as well as introduction of any other or new therapeutic substances for the treatment of COVID-19.
One common element in many value-based programs is risk adjustment using Hierarchical Condition Categories (HCCs) to create a Risk Adjustment Factor (RAF) score. This method ranks diagnoses into categories that represent conditions with similar cost patterns.
Why are so many AKI records being denied? It’s hard to give one answer for why so many AKI records are being denied lately, but most appear to be due to the multiple sets of criteria available for use in determining if a patient has AKI, as well as physician documentation. As stated in Part 3 of this series, there are three main criteria/classifications used to diagnose AKI.
In previous parts of this series we looked at the definitions of AKI/ARF, causes, coding and sequencing, and the common clinical indicators that patients present with that are diagnosed with this condition. In Part 4, we will look at the documentation that should be present to report the diagnosis without fear of denial, as well as when a query is needed to clarify the diagnosis.
If the facility does a COVID-19 test, and test is negative, do I need a diagnosis code. The answer is yes, you will report a Z-code. The Z-code depends on the record documentation and circumstances of testing. For any patient receiving a COVID-19 test, if negative, there MUST e a Z-code to describe why the test was taken. (Test negative for COVID-19 and MD does not override negative results).
The FY2021 IPPS Proposed Rule is out and here are some highlights from it regarding ICD-10 Code proposals. We will know if these changes are permanent after the public comment period is over on July 10, 2020 and CMS prepares the Final Rule, usually out by August 1.
As discussed in Part 1 of this series, AKI/ARF is a common diagnosis that coders see daily. In Part 2, we are going to focus on the different types/specificity of AKI/ARF. We’ll learn what they mean, as well as how to code the diagnosis.
This is part 1 in a series focused on coding of acute kidney injury (AKI) and/or acute renal failure (ARF). AKI/ARF is reported often, but is also one of the most common diagnosis found in denials.
With the proliferation of COVID-19 cases, we thought we would put together a quick reference listing of some of the common scenarios that coders have asked about. As with all coding, coders should follow Official Guidelines for Coding and Reporting and the COVD-19 Frequently Asked Questions document by the AHA.
Effective March 1, Medicare will pay physicians for telehealth services at the same rate as in-person visits for all diagnoses, not just services related to COVID-19. This great for providers whose patients are reluctant to visit the office.
The biggest reasons why some hospital systems are moving to single path coding is to eliminate duplicative processes and to optimize productivity. In addition, costs are reduced when only one coder “touches” the record and completes both types of coding.